$120.20
1.64% today
Nasdaq, Nov 04, 09:16 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Target price 2024 - Analyst rating & recommendation

Neurocrine Biosciences, Inc. Classifications & Recommendation:

Buy
86%
Hold
14%

Neurocrine Biosciences, Inc. Price Target

Target Price $163.63
Price $122.21
Potential
Number of Estimates 24
24 Analysts have issued a price target Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. target price is $163.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 29 analysts: 25 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Neurocrine Biosciences, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 1.89 2.35
26.76% 24.42%
EBITDA Margin 22.05% 30.64%
23.26% 38.96%
Net Margin 13.25% 19.11%
24.91% 44.27%

25 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2024 . The average Neurocrine Biosciences, Inc. sales estimate is

$2.3b
Unlock
. This is
4.69% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.4b 6.03%
Unlock
, the lowest is
$2.2b 1.24%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.9b 26.76%
2024
$2.3b 24.42%
Unlock
2025
$2.7b 16.55%
Unlock
2026
$3.2b 16.50%
Unlock
2027
$3.6b 12.68%
Unlock
2028
$4.0b 12.15%
Unlock

8 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2024. The average Neurocrine Biosciences, Inc. EBITDA estimate is

$719m
Unlock
. This is
17.16% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$934m 52.14%
Unlock
, the lowest is
$616m 0.33%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $416m 56.25%
2024
$719m 72.88%
Unlock
2025
$869m 20.84%
Unlock
2026
$1.2b 40.18%
Unlock
2027
$1.6b 32.12%
Unlock
2028
$1.9b 17.79%
Unlock

EBITDA Margin

2023 22.05% 23.26%
2024
30.64% 38.96%
Unlock
2025
31.77% 3.69%
Unlock
2026
38.22% 20.30%
Unlock
2027
44.82% 17.27%
Unlock
2028
47.07% 5.02%
Unlock

23 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2024. The average Neurocrine Biosciences, Inc. net profit estimate is

$449m
Unlock
. This is
18.84% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$667m 76.68%
Unlock
, the lowest is
$340m 9.97%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $250m 58.33%
2024
$449m 79.47%
Unlock
2025
$651m 45.06%
Unlock
2026
$903m 38.82%
Unlock
2027
$1.1b 21.41%
Unlock
2028
$1.3b 21.50%
Unlock

Net Margin

2023 13.25% 24.91%
2024
19.11% 44.27%
Unlock
2025
23.78% 24.44%
Unlock
2026
28.34% 19.18%
Unlock
2027
30.53% 7.73%
Unlock
2028
33.08% 8.35%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 2.47 4.43
58.33% 79.35%
P/E 27.57
EV/Sales 4.87

23 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$4.43
Unlock
. This is
18.77% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$6.59 76.68%
Unlock
, the lowest is
$3.36 9.92%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $2.47 58.33%
2024
$4.43 79.35%
Unlock
2025
$6.43 45.15%
Unlock
2026
$8.93 38.88%
Unlock
2027
$10.84 21.39%
Unlock
2028
$13.17 21.49%
Unlock

P/E ratio

Current 32.74 46.32%
2024
27.57 15.79%
Unlock
2025
19.01 31.05%
Unlock
2026
13.69 27.99%
Unlock
2027
11.28 17.60%
Unlock
2028
9.28 17.73%
Unlock

Based on analysts' sales estimates for 2024, the Neurocrine Biosciences, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.10 11.61%
2024
4.87 4.53%
Unlock
2025
4.18 14.20%
Unlock
2026
3.59 14.16%
Unlock
2027
3.18 11.25%
Unlock
2028
2.84 10.83%
Unlock

P/S ratio

Current 5.52 10.89%
2024
5.27 4.48%
Unlock
2025
4.52 14.20%
Unlock
2026
3.88 14.16%
Unlock
2027
3.44 11.25%
Unlock
2028
3.07 10.83%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today